Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2025-12-26 @ 3:28 AM
Study NCT ID:
NCT00911820
Status:
COMPLETED
Last Update Posted:
2022-11-08
First Post:
2009-05-29
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-07
Start Date Type:
ACTUAL
Primary Completion Date:
2012-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-08
Completion Date Type:
ACTUAL
First Submit Date:
2009-05-29
First Submit QC Date:
None
Study First Post Date:
2009-06-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-08-31
Results First Submit QC Date:
None
Results First Post Date:
2017-11-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-13
Last Update Post Date:
2022-11-08
Last Update Post Date Type:
ACTUAL